

- ning products - Regulations in Europe and North America. *Eur. J. Intern. Med.* 2018;49:2-6.
6. [Internet] Státní agentura pro konopí pro léčebné účely. Available from: <https://www.sakl.cz/konopi/>.
 7. Mechoulam R, Gaoni Y. Recent advances in the chemistry of hashish. *Fortschr. Chem. Org. Naturst.* 1967;25:175-213.
 8. Elsohly MA, Slade D. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. *Life Sci.* 2005;78(5):539-548.
 9. Devane WA, Hanuš L, Breuer A, Pertwee RG, Stevenson LA, Griffín G, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. *Science.* 1992;258(5090):1946-1949.
 10. Šulcová A, Landa L. Farmakodynamika kanabinoidů a přehled jejich možného terapeutického využití. In: Landa L. (ed.) *Léčebné konopí v současné medicínské praxi*. Praha: Grada Publishing; 2020, 58-67. ISBN 978-80-247-3967-0.
 11. Storzshuk MV, Zholos AV. TRP Channels as novel targets for endogenous ligands: Focus on endocannabinoids and nociceptive signalling. *Curr. Neuropharmacol.* 2018;16(2):137-150.
 12. Lowe H, Toyang N, Steele B, Bryant J, Ngwa W. The endocannabinoid system: A potential target for the treatment of various diseases. *Int. J. Mol. Sci.* 2021; 22(17):9472.
 13. Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. *J. Am. Chem. Soc.* 1964;86(8):1646-1647.
 14. Le Boisselier R, Alexandre J, Lelong-Boulouard V, Debruyne D. Focus on cannabinoids and synthetic cannabinoids. *Clin. Pharmacol. Ther.* 2017;101(2):220-229.
 15. Morales P, Hurst DP, Reggio PH. Molecular targets of the phytocannabinoids: A complex picture. *Prog. Chem. Org. Nat. Prod.* 2017;103:103-131.
 16. Preedy VR. *Handbook of Cannabis and related pathologies: Biology, Pharmacology, Diagnosis, and Treatment*. London: Academic Press; 2017. ISBN 978-0-12-800756-3
 17. Mechoulam R, Shvo Y. The structure of cannabidiol. *Tetrahedron.* 1963;19(12):2073-2078.
 18. Peng J, Fan M, An C, Ni F, Huang W, Luo J. A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD). *Basic. Clin. Pharmacol. Toxicol.* 2022;130(4):439-456.
 19. Laprairie RB, Bagher AM, Kelly ME, Denovan-Wright EM. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. *Br. J. Pharmacol.* 2015;172(20):4790-4805.
 20. Morales P, Hurst DP, Reggio PH. Molecular targets of the phytocannabinoids: A complex picture. *Prog. Chem. Org. Nat. Prod.* 2017;103:103-31.
 21. Ghovanloo MR, Shuart NG, Mezeyova J, Dean RA, Ruben PC, Goodchild SJ. Inhibitory effects of cannabidiol on voltage-dependent sodium currents. *J. Biol. Chem.* 2018;293(43):16546-16558.
 22. Rodriguez-Munoz M, Onetti Y, Cortes-Montero E, Garzon J, Sanchez-Blazquez P. Cannabidiol enhances morphine antinociception, diminishes NMDA-mediated seizures and reduces stroke damage via the sigma 1 receptor. *Mol. Brain.* 2018;11(1):51.
 23. Hanuš L, Šulcová A, Landa L. Kanabinoidní látky a léčivá síla konopí. In: Landa L. (ed.) *Léčebné konopí v současné medicínské praxi*. Praha: Grada Publishing; 2020, 38-57. ISBN 978-80-247-3967-0.
 24. Calapai F, Cardia L, Esposito E, Ammendolia I, Mondello C, Lo Giudice R, et al. Pharmacological aspects and biological effects of cannabigerol and its synthetic derivatives. *Evid. Based. Complement. Alternat. Med.* 2022;3336516.
 25. Juřica J. Farmakokinetika a léčivé interakce kanabinoidů. In: Landa L. (ed.) *Léčebné konopí v současné medicínské praxi*. Praha: Grada Publishing; 2020, 68-82. ISBN 978-80-247-3967-0.
 26. Gaston TE, Friedman D. Pharmacology of cannabinoids in the treatment of epilepsy. *Epilepsy Behav.* 2017;70(Pt B):313-318.
 27. Harvey DJ, Samara E, Mechoulam R. Urinary metabolites of cannabidiol in dog, rat and man and their identification by gas chromatography-mass spectrometry. *J. Chromatogr.* 1991;562(1-2):299-322.
 28. Newmeyer MN, Swortwood MJ, Barnes AJ, Abulseoud OA, Scheidweiler KB, Huestis MA. Free and glucuronide whole blood cannabinoids' pharmacokinetics after controlled smoked, vaporized, and oral cannabis administration in frequent and occasional cannabis users: Identification of recent cannabis intake. *Clin. Chem.* 2016;62(12):1579-1592.
 29. MacCallum CA, Russo EB. Practical considerations in medical cannabis administration and dosing. *Eur. J. Intern. Med.* 2018;49:12-19.
 30. Vandrey R, Herrmann ES, Mitchell JM, Bigelow GE, Flegel R, LoDico C, et al. Pharmacokinetic profile of oral cannabis in humans: Blood and oral fluid disposition and relation to pharmacodynamic outcomes. *J. Anal. Toxicol.* 2017;41(2):83-99.
 31. van den Elsen GA, Ahmed AI, Lammers M, Kramers C, Verkes RJ, van der Marck MA, et al. Efficacy and safety of medical cannabinoids in older subjects: a systematic review. *Ageing Res. Rev.* 2014;14:56-64.
 32. Trojan V, Landa L, Hrib R, Jurica J, Rychlickova J, Zvonicek V, et al. Assessment of delta-9-tetrahydrocannabinol (THC) in saliva and blood after oral administration of medical cannabis with respect to its effect on driving abilities. *Physiol. Res.* 2022 Nov 28;71(5):703-712.
 33. Landa L, Jurica J, Sliva J, Pechackova M, Demlova R. Medical cannabis in the treatment of cancer pain and spastic conditions and options of drug delivery in clinical practice. *Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub.* 2018;162(1):18-25.
 34. [Internet] Státní agentura pro konopí pro léčebné účely. Available from: <http://www.sakl.cz/lekari/informace-pro-lekare>.
 35. [Internet] Státní agentura pro konopí pro léčebné účely. Available from: <http://www.sakl.cz/pacienti/nezadouci>.
 36. Hřib R, Pecháčková M, Šaloun J. Kanabinoidy v léčbě chronické neoplastické bolesti. In: Landa L. (ed.) *Léčebné konopí v současné medicínské praxi*. Praha: Grada Publishing; 2020, 83-96. ISBN 978-80-247-3967-0.
 37. Aviram J, Pud D, Gershoni T, Schiff-Keren B, Ogintz M, Vulfsons S, et al. Medical cannabis treatment for chronic pain: Outcomes and prediction of response. *Eur. J. Pain.* 2021;25(2):359-374.
 38. Abelev S, Warne LN, Benson M, Hardy M, Nayee S, Barlow J. Medicinal Cannabis for the Treatment of Chronic Refractory Pain: An Investigation of the Adverse Event Profile and Health-Related Quality of Life Impact of an Oral Formulation. *Med Cannabis Cannabinoids.* 2022 Feb 9;5(1):20-31. doi: 10.1159/000521492. PMID: 35950052; PMCID: PMC9235063.
 39. Greis A, Larsen E, Liu C, Renslo B, Radakrishnan A, Wilson-Poe AR. Perceived efficacy, reduced prescription drug use, and minimal side effects of cannabis in patients with chronic orthopedic pain. *Cannabis Cannabinoid Res.* 2022;7(6):865-875.
 40. Hjorthøj C, La Cour P, Nordentoft M, Posselt CM. Cannabis-based medicines and medical cannabis for patients with neuropathic pain and other pain disorders: Nationwide register-based pharmacoepidemiologic comparison with propensity score matched controls. *Eur. J. Pain.* 2022;26(2):480-491.
 41. Žyga J. A review of studies evaluating medical cannabis for the chronic pain management. *J. Educ. Health Sport.* 2022;12(8):250-256.
 42. Ng JY, Abrams A, Pathak A, Tahir U, Jomy J. What are the experiences of patients using cannabis for pain? A systematic review of qualitative studies. *Eur. J. Integr. Med.* 2022;49:102098.

S NÁMI SE NEZTRATÍTE

Časopis je indexován v těchto databázích: Scopus, WOS, Embase, Bibliographia medica čechoslovaca, Excerpta medica a Academic Search Complete

Využíváme systém **CrossRef**. S články můžete snadno pracovat díky jednoznačnému identifikátoru **DOI**.

